{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:20:59Z","timestamp":1787757659107,"version":"build-2784847793"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Anti-tumor necrosis factor-alpha (anti-TNF-\u03b1) agents have been widely used in the treatment of rheumatic and autoimmune diseases. It was thought that TNF-\u03b1 blockage could be an appropriate choice in the treatment of multiple sclerosis (MS), however; dose-dependent increase in magnetic resonance imaging (MRI) activity, and frequency and severity of relapses were reported in individuals with MS in clinical studies. Herein a 32-year-old lady diagnosed with ankylosing spondylitis who developed progressive gait disturbance after adalimumab treatment has been presented. Brain and spinal cord MRI revealed demyelinating lesions and oligoclonal bands were positive, in the cerebrospinal fluid. Ocrelizumab treatment was initiated for progressive demyelinating disorder. Patients scheduled for anti-TNF-\u03b1 treatment should be carefully evaluated for demyelinating diseases, and patients receiving this treatment should be closely monitored for emerging neurological findings. In individuals with demyelinating disease related to anti-TNF- \u03b1 treatment, decisions on long-term immunomodulatory treatment should be tailored for each patient.<\/jats:p>","DOI":"10.4103\/neuroindia.ni_371_20","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T16:00:48Z","timestamp":1753372848000},"page":"791-793","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Progressive Demyelinating Disease Associated with Adalimumab Treatment in a Patient Diagnosed with Ankylosing Spondylitis"],"prefix":"10.4103","volume":"73","author":[{"given":"Mehmet Fatih","family":"Yetkin","sequence":"first","affiliation":[{"name":"Department of Neurology, Erciyes University, School of Medicine, Kayseri, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeyma","family":"Benli","sequence":"additional","affiliation":[{"name":"Department of Neurology, Erciyes University, School of Medicine, Kayseri, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Mirza","sequence":"additional","affiliation":[{"name":"Department of Neurology, Erciyes University, School of Medicine, Kayseri, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"R1-20260422","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R2-20260422","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: Structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology (Oxford, England)"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1177\/1352458512461969","article-title":"Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy","volume":"19","author":"Cereda","year":"2013","journal-title":"Mult Scler (Houndmills, Basingstoke, England)"},{"key":"R4-20260422","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00415-016-8238-5","article-title":"Extensive and severe CNS demyelination associated with golimumab therapy","volume":"263","author":"Maillart","year":"2016","journal-title":"J Neurol"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS Demyelination with TNF-alpha Blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R6-20260422","doi-asserted-by":"crossref","first-page":"105887","DOI":"10.1016\/j.clineuro.2020.105887","article-title":"A case of fulminant demyelinating disease associated with golimumab treatment","volume":"195","author":"Yetkin","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"Van Oosten","year":"1996","journal-title":"Neurology"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"R9-20260422","first-page":"728371","article-title":"Case report of transverse myelitis in a patient receiving etanercept for rheumatoid arthritis","volume":"2013","author":"Defty","year":"2013","journal-title":"Case Rep Rheumatol"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00296-011-2316-x","article-title":"Optic neuritis after infliximab therapy","volume":"33","author":"Faillace","year":"2013","journal-title":"Rheumatol Int"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"1756286419895155","DOI":"10.1177\/1756286419895155","article-title":"PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-\u03b1 therapy-associated demyelinating disorders","volume":"13","author":"Engel","year":"2020","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Neurology India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/neuroindia.NI_371_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:48:21Z","timestamp":1787755701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/neuroindia.NI_371_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/neuroindia.ni_371_20","relation":{},"ISSN":["0028-3886","1998-4022"],"issn-type":[{"value":"0028-3886","type":"print"},{"value":"1998-4022","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2020-04-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}